对药物和生物制品随机临床试验中的共变量进行调整
1Division of Biometrics IV, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Clinical trials (London, England)
|December 31, 2025
概括
美国食品和药物管理局 (FDA) 现在在药物和生物制剂的随机临床试验中接受共变量调整. 这种方法比未经调整的分析具有优势,提高了试验的效率和可靠性.
科学领域:
- 临床试验方法论 临床试验方法论
- 生物统计学 生物统计学
- 监管科学 监管科学
背景情况:
- 美国食品和药物管理局 (FDA) 在2023年5月发布了关于制药和生物制品随机临床试验 (RCT) 协变量调整的指南.
- 共变量调整是一种用于控制可能影响试验结果的变量影响的统计技术.
- 了解FDA的建议对于有效设计和分析临床试验至关重要.
研究的目的:
- 总结一下FDA关于临床试验中的共变量调整指南背后的逻辑.
- 概述FDA指导文件中提供的关键建议.
- 讨论在大型和小型临床试验中实施协变量调整的考虑因素.
主要方法:
- 美国食品和药物管理局2023年5月指导文件的审查和综合.
- 对指导的动机,建议和影响进行分析.
- 探索在不同试验环境中对共变量调整的实际考虑.
主要成果:
- 与共变量调整的预规定的初级分析相比,与未调整的分析相比,可以提供显著的优势.
- 美国食品和药物管理局 (FDA) 一般接受在分析临床试验数据时使用共变量调整.
- 该指南针对大型和小型试验的考虑,承认应用中的潜在差异.
结论:
- 共变量调整是临床试验分析中的一个有价值的工具,由最近的FDA指导支持.
- 实施共变量调整需要仔细考虑试验设计和统计方法.
- 在特定场景中,进一步就共同变量调整的最佳实践达成共识可能是有益的.
更多相关视频
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.1K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
1.1K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
376
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
376
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
Randomized Experiments
8.8K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
8.8K
Dosage Regimen: Individualization
151
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
151
